🚀 VC round data is live in beta, check it out!
AnteoTech Valuation Multiples
Discover revenue and EBITDA valuation multiples for AnteoTech and similar public comparables like Integrum, Impedimed, aap Implantate, Iridex and more.
AnteoTech Overview
About AnteoTech
AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.
Founded
1995
HQ
Employees
40
Website
Financials (LTM)
EV
$25M
AnteoTech Financials
AnteoTech reported last 12-month revenue of $1M and negative EBITDA of ($2M).
In the same LTM period, AnteoTech generated ($2M) in EBITDA losses and had net loss of ($2M).
Revenue (LTM)
AnteoTech P&L
In the most recent fiscal year, AnteoTech reported revenue of $683K and EBITDA of ($4M).
AnteoTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $683K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $683K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | ($2M) | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | (150%) | XXX | (542%) | XXX | XXX | XXX |
| EBIT Margin | (222%) | XXX | (646%) | XXX | XXX | XXX |
| Net Profit | ($2M) | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | (217%) | XXX | (646%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AnteoTech Stock Performance
AnteoTech has current market cap of $25M, and enterprise value of $25M.
Market Cap Evolution
AnteoTech's stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25M | $25M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnteoTech Valuation Multiples
AnteoTech trades at 23.7x EV/Revenue multiple, and (15.9x) EV/EBITDA.
EV / Revenue (LTM)
AnteoTech Financial Valuation Multiples
As of March 24, 2026, AnteoTech has market cap of $25M and EV of $25M.
Equity research analysts estimate AnteoTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AnteoTech has a P/E ratio of (11.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV/Revenue | 23.7x | XXX | 36.4x | XXX | XXX | XXX |
| EV/EBITDA | (15.9x) | XXX | (6.7x) | XXX | XXX | XXX |
| EV/EBIT | (10.7x) | XXX | (5.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 36.4x | XXX | XXX | XXX |
| P/E | (11.1x) | XXX | (5.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AnteoTech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AnteoTech Margins & Growth Rates
AnteoTech's revenue in the last 12 month grew by 83%.
AnteoTech's revenue per employee in the last FY averaged $0.0M.
AnteoTech's rule of 40 is (67%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AnteoTech's rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
AnteoTech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 83% | XXX | 75% | XXX | XXX | XXX |
| EBITDA Margin | (150%) | XXX | (542%) | XXX | XXX | XXX |
| EBITDA Growth | (87%) | XXX | (79%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (67%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 66% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 763% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 65% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1055% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AnteoTech Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Integrum | XXX | XXX | XXX | XXX | XXX | XXX |
| Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
| aap Implantate | XXX | XXX | XXX | XXX | XXX | XXX |
| Iridex | XXX | XXX | XXX | XXX | XXX | XXX |
| Finemedix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AnteoTech M&A Activity
AnteoTech acquired XXX companies to date.
Last acquisition by AnteoTech was on XXXXXXXX, XXXXX. AnteoTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AnteoTech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnteoTech Investment Activity
AnteoTech invested in XXX companies to date.
AnteoTech made its latest investment on XXXXXXXX, XXXXX. AnteoTech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AnteoTech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AnteoTech
| When was AnteoTech founded? | AnteoTech was founded in 1995. |
| Where is AnteoTech headquartered? | AnteoTech is headquartered in Australia. |
| How many employees does AnteoTech have? | As of today, AnteoTech has over 40 employees. |
| Is AnteoTech publicly listed? | Yes, AnteoTech is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of AnteoTech? | AnteoTech trades under ADO ticker. |
| When did AnteoTech go public? | AnteoTech went public in 2000. |
| Who are competitors of AnteoTech? | AnteoTech main competitors are Integrum, Impedimed, aap Implantate, Iridex. |
| What is the current market cap of AnteoTech? | AnteoTech's current market cap is $25M. |
| What is the current revenue of AnteoTech? | AnteoTech's last 12 months revenue is $1M. |
| What is the current revenue growth of AnteoTech? | AnteoTech revenue growth (NTM/LTM) is 83%. |
| What is the current EV/Revenue multiple of AnteoTech? | Current revenue multiple of AnteoTech is 23.7x. |
| Is AnteoTech profitable? | No, AnteoTech is not profitable. |
| What is the current EBITDA of AnteoTech? | AnteoTech has negative EBITDA and is not profitable. |
| What is AnteoTech's EBITDA margin? | AnteoTech's last 12 months EBITDA margin is (150%). |
| What is the current EV/EBITDA multiple of AnteoTech? | Current EBITDA multiple of AnteoTech is (15.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.